Dr. Xin Yin 殷欣
Chief Physician
Department of Medical Oncology (Liver Tumors), Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of benign and malignant liver tumors, including primary liver cancer, cholangiocarcinoma, and metastatic liver cancer. Specializes in interventional therapy, ablation, targeted therapy, immunotherapy, and ultrasound-guided interventions for benign liver tumors.
Dr. Xin Yin is a Chief Physician in the Department of Liver Medical Oncology at Zhongshan Hospital, Fudan University, and a master’s supervisor. Holding a PhD in Internal Medicine (Gastroenterology) from Fudan University Shanghai Medical College, Dr. Yin has practiced at Zhongshan Hospital for 20 years. Research findings have been presented at international conferences such as ASCO and APPLE.
Name order: in Chinese the family name comes first (Yin Xin). Papers usually list the name as Xin Yin or Yin X.
Selected publications
45 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Biol Sci, 2025 (senior author): Increased CAPG inhibits ferroptosis to drive tumor proliferation and sorafenib resistance in hepatocellular carcinoma via the WDR74-p53-SLC7A11 pathway. PubMed 40959275
- J Hepatocell Carcinoma, 2025 (senior author): Predicting Resistance and Survival of HCC Patients Post-HAIC: Based on Shapley Additive exPlanations and Machine Learning. PubMed 40475092
- J Imaging Inform Med, 2024 (senior author): Development and Preliminary Validation of a Novel Convolutional Neural Network Model for Predicting Treatment Response in Patients with Unresectable Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy. PubMed 38393621
- Ther Adv Med Oncol, 2024 (senior author): Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy for hepatocellular carcinoma patients with portal vein tumor thrombus. PubMed 38617024
- Cell Mol Gastroenterol Hepatol, 2024 (senior author): DDR2/STAT3 Positive Feedback Loop Mediates the Immunosuppressive Microenvironment by Upregulating PD-L1 and Recruiting MDSCs in Oxaliplatin-Resistant HCC. PubMed 38969205
- MedComm (2020), 2023 (senior author): NLRP3/IL-1β induced myeloid-derived suppressor cells recruitment and PD-L1 upregulation promotes oxaliplatin resistance of hepatocellular carcinoma. PubMed 38116060
- Am J Cancer Res, 2023 (senior author): LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma. PubMed 38058825
- Cell Mol Gastroenterol Hepatol, 2023 (senior author): Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment. PubMed 36513250
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion